Mobile

VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate th...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001363-31

VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and efficacy of paricalcitol capsules on albuminuria reduction in CKD subjects with Type 2 diabetic nephropathy receiving optimal ACEi and/or Angiotensin II-Receptor-Blocker therapy

Critère d'inclusion

  • Type 2 diabetic nephropathy

Liens